Jasper Therapeutics(US:JSPR) Globenewswire·2025-10-20 00:18Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The lead plaintiff must file a motion with the court by November 18, 2025, to represent other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact its products' regulatory and commercial prospects [5] - Specific claims include the lack of necessary controls for third-party manufacturers, increased risk of confounded study results, and overstated business and financial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages [5]